Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.69 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 6/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 2/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625154 | 0.93 | ABCB1 (0.69) | ABCB1NOX1ALOX5PTPN1MAPT | |
| SCHEMBL717762 | 0.91 | ABCB1 (0.68) | ABCB1NOX1ALOX5PTPN1MAPT | |
| SCHEMBL13679699 | 0.86 | ABCB1 (0.92) | ABCB1NOX1ALOX5PTPN1MAPT | |
| SCHEMBL3830858 | 0.86 | ABCB1 (0.92) | ABCB1NOX1ALOX5PTPN1MAPT | |
| SCHEMBL3860839 | 0.86 | NOX1 (0.55) | ABCB1NOX1ALOX5PTPN1MAPT | |
| SCHEMBL6621640 | 0.84 | ABCB1 (0.57) | ABCB1NOX1ALOX5PTPN1MAPT | |
| SCHEMBL4442601 | 0.84 | ABCB1 (0.68) | ABCB1NOX1ALOX5PTPN1MAPT | |
| SCHEMBL3824112 | 0.83 | ABCB1 (0.60) | ABCB1NOX1ALOX5PTPN1MAPT | |
| SCHEMBL16448288 | 0.83 | ABCB1 (0.68) | ABCB1NOX1ALOX5PTPN1MAPT | |
| SCHEMBL718305 | 0.83 | ABCB1 (0.68) | ABCB1NOX1ALOX5PTPN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0999835-B1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | TAIJI BIOMEDICAL INC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-0999835-B1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | TAIJI BIOMEDICAL INC (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2082740-A2 | Use of imidazole derivatives as MDR modulators | Taiji Biomedical, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2082740-A2 | Use of imidazole derivatives as MDR modulators | Taiji Biomedical, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-0999835-A4 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5840721-A | INCREASE SENSITIVITY OF MULTIDRUG RESISTANT TUMOR CELLS TO ANTICANCER AGENTS | ONTOGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |